摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

naphthalen-2-ylmethyl-(5-pyrimidin-5-yl-pyridin-3-yl)-amine | 767342-31-4

中文名称
——
中文别名
——
英文名称
naphthalen-2-ylmethyl-(5-pyrimidin-5-yl-pyridin-3-yl)-amine
英文别名
naphtalen-2-ylmethyl-(5-pyrimidin-5-yl-pyridin-3-yl)-amine;3-Pyridinamine, N-(2-naphthalenylmethyl)-5-(5-pyrimidinyl)-;N-(naphthalen-2-ylmethyl)-5-pyrimidin-5-ylpyridin-3-amine
naphthalen-2-ylmethyl-(5-pyrimidin-5-yl-pyridin-3-yl)-amine化学式
CAS
767342-31-4
化学式
C20H16N4
mdl
——
分子量
312.374
InChiKey
DWQFOLAPGXZGKS-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    24
  • 可旋转键数:
    4
  • 环数:
    4.0
  • sp3杂化的碳原子比例:
    0.05
  • 拓扑面积:
    50.7
  • 氢给体数:
    1
  • 氢受体数:
    4

文献信息

  • PYRAZINE AND PYRIDINE DERIVATIVES AS RHO KINASE INHIBITORS
    申请人:Biofocus Discovery Ltd
    公开号:EP1644365A2
    公开(公告)日:2006-04-12
  • Compounds Which Bind to the Active Site of Protein Kinase Enzymes
    申请人:Birault Veronique
    公开号:US20090163515A1
    公开(公告)日:2009-06-25
    The present invention relates to a compound and a group of compounds which are inhibitors of Rho kinase (ROK, ROCK). In addition, the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, glaucoma and AIDS. The compounds can be used in screening programmes against protein kinases. The invention also provides methods for making compounds and libraries that include these compounds.
  • [EN] COMPOUND LIBRARIES<br/>[FR] BIBLIOTHEQUE DE COMPOSES
    申请人:BIOFOCUS DISCOVERY LTD
    公开号:WO2004085409A2
    公开(公告)日:2004-10-07
    The present invention relates to pyridine,pyrazine,imidoz[1,2a]pyrazine and 1H-imidoz[4,5-b]pyrazin-2-one compounds capable of binding to the active site of protein kinase enzymes. The invention further relates to libraries of these compounds and a family of libraries of these compounds for use in screening programmes against protein kinases as well as the individual compounds for use in hit to lead and lead optimisation projects, and similar stages in the drug discovery process. The invention also provides methods for making compounds and libraries, thereof.
  • [EN] COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES<br/>[FR] COMPOSES SE LIANT AU SITE ACTIF D'ENZYMES PROTEINE KINASES
    申请人:BIOFOCUS DISCOVERY LTD
    公开号:WO2005003101A2
    公开(公告)日:2005-01-13
    The present invention relates to a compound and a group of compounds of formula (I) and (II) with the definitions of R1 -R6 according to claim 1 which are inhibitors of Rho kinase (ROK, ROCK). In addition, the invention relates to methods of treatment and use of the compounds in the manufacture of a medicament for application to a number of therapeutic indications including cardiovascular disease (coronary vasospasm, hypertensive disease, arteriosclerosis), stroke, cancer, erectile dysfunction, asthma, osteoporosis, glaucoma and AIDS. The compounds can be used in screening programmes against protein kinases. The invention also provides methods for making compounds and libraries that include these compounds.
  • [EN] COMPOUNDS WHICH BIND TO THE ACTIVE SITE OF PROTEIN KINASE ENZYMES<br/>[FR] COMPOSES SE LIANT AU SITE ACTIF DES PROTEINES KINASES
    申请人:BIOFOCUS DISCOVERY LTD
    公开号:WO2006072792A2
    公开(公告)日:2006-07-13
    [EN] One or more compounds that are inhibitors of a serine/ threonine kinase, more particularly Rho kinase (ROK, ROCK) can be used in the manufacture of a medicament for treatment or prophylaxis of a condition selected from: an ocular condition including age related macular degeneration, lacrimal gland disease or diabetic retinopathy, or suppression of neurite growth and hence a condition requiring nerve cell extension and connectivity, neuronal regeneration, inducing new axonal growth and promotion of axonal (re)wiring, repairing damage to neurons in the CNS caused by trauma (eg stroke, traumatic brain injury etc.) or neurodegeneration (eg Alzheimer's, Parkinson's etc), repair and recovery from and treatment of disorders such as spinal cord injury and in reducing the subsequent effects thereof, or pain caused by nerve cell damage such as following trauma or amputation for example in the treatment of neuropathic pain. The compounds are selected from the specific group of compounds that comprises or consists of compounds of formula (I) or (II) wherein R1, R2, R3, R4, R5 and R6 are defined herein.
    [FR] L'invention concerne un ou plusieurs composés qui sont des inhibiteurs d'une sérine/thréonine kinase et, d'une manière plus spécifique, de la Rho kinase (ROK, ROCK). Ces composés peuvent être utilisé dans la fabrication d'un médicament pour le traitement ou la prévention d'une maladie choisie dans le groupe constitué : d'une affection oculaire telle que la dégénérescence maculaire liée à l'âge, une maladie de la glande lacrymale ou la rétinopathie diabétique ou la suppression du développement de neurites et donc à une affection nécessitant l'extension et la connectivité de cellules nerveuses, la régénération des neurones, l'induction du développement de nouveaux axones et la promotion du (re)câblage d'axones, la réparation de lésions des neurones dans le SNC provoquées par un traumatisme (par exemple un accident cérébrovasculaire, une lésion cérébrale traumatique, etc.) ou par une neurodégénérescence (par exemple la maladie d'Alzheimer, la maladie de Parkinson, etc.), à la réparation ou la récupération de troubles tels qu'une lésion de la moelle épinière et le traitement de ceux-ci et la réduction des effets subséquents de ceux-ci ou de la douleur provoquée par une lésion des cellules nerveuses telle que celle consécutive à un traumatisme ou à une amputation par exemple dans le traitement de la douleur neuropathique. Les composés selon l'invention sont choisis dans un groupe spécifique de composés qui comprend des composés représentés par la formule (I) ou (II), dans laquelle R1, R2, R3, R4, R5 et R6 sont tels que définis dans le descriptif.
查看更多